Tyra Biosciences (TYRA) Gains from Investment Securities (2020 - 2026)
Quarterly Gains from Investment Securities rose 1227.07% to $160.3 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $172.2 million through Mar 2026, up 289.55% year-over-year, with the annual reading at $13.6 million for FY2025, 30.16% up from the prior year.
Tyra Biosciences filings provide 7 years of Gains from Investment Securities readings, the most recent being $160.3 million for Q1 2026.
- Gains from Investment Securities hit $160.3 million in Q1 2026 for Tyra Biosciences, up from $13.6 million in the prior quarter.
- Across five years, Gains from Investment Securities topped out at $160.3 million in Q1 2026 and bottomed at -$729000.0 in Q4 2022.
- Average Gains from Investment Securities over 5 years is $14.0 million, with a median of $776948.0 recorded in 2023.
- The largest annual shift saw Gains from Investment Securities crashed 104.99% in 2024 before it soared 23853.02% in 2025.
- Tyra Biosciences' Gains from Investment Securities stood at -$729000.0 in 2022, then soared by 649.38% to $4.0 million in 2023, then crashed by 104.99% to -$200000.0 in 2024, then surged by 6908.72% to $13.6 million in 2025, then soared by 1076.85% to $160.3 million in 2026.
- Per Business Quant, the three most recent readings for TYRA's Gains from Investment Securities are $160.3 million (Q1 2026), $13.6 million (Q4 2025), and $4.2 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn |
| 10 | Tyra Biosciences | 2.03 Bn | 2.03 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 160.26 Mn |
| Mar 31, 2026 | 160.26 Mn |
| Dec 31, 2025 | 13.62 Mn |
| Dec 31, 2025 | 13.62 Mn |
| Sep 30, 2025 | 4.17 Mn |
| Sep 30, 2025 | 4.17 Mn |
| Jun 30, 2025 | 630,585.00 |
| Jun 30, 2025 | 630,585.00 |
| Mar 31, 2025 | 12.08 Mn |
| Mar 31, 2025 | 12.08 Mn |
| Dec 31, 2024 | -200,000.00 |
| Dec 31, 2024 | -200,000.00 |
| Sep 30, 2024 | 17,389.00 |
| Sep 30, 2024 | 17,389.00 |
| Jun 30, 2024 | 100,000.00 |
| Jun 30, 2024 | 100,000.00 |
| Mar 31, 2024 | 32.24 Mn |
| Mar 31, 2024 | 32.24 Mn |
| Dec 31, 2023 | 4.01 Mn |
| Dec 31, 2023 | 4.01 Mn |
| Sep 30, 2023 | 8.11 Mn |
| Sep 30, 2023 | 8.11 Mn |
| Jun 30, 2023 | 776,948.00 |
| Jun 30, 2023 | 776,948.00 |
| Mar 31, 2023 | 541,300.00 |
| Mar 31, 2023 | 541,300.00 |
| Dec 31, 2022 | -729,000.00 |
| Dec 31, 2022 | -729,000.00 |
| Sep 30, 2022 | 2.63 Mn |
| Sep 30, 2022 | 2.63 Mn |
| Jun 30, 2022 | 100,000.00 |
| Jun 30, 2022 | 100,000.00 |
| Mar 31, 2022 | 190,487.00 |
| Mar 31, 2022 | 190,487.00 |
| Dec 31, 2021 | -1.23 Mn |
| Dec 31, 2021 | -1.23 Mn |
| Sep 30, 2021 | 2.09 Mn |
| Sep 30, 2021 | 2.09 Mn |
| Jun 30, 2021 | 1.22 Mn |
| Jun 30, 2021 | 1.22 Mn |
| Dec 31, 2020 | 88,000.00 |
| Dec 31, 2020 | 88,000.00 |